Immunosuppressive, antiviral and antitumor activities of cytarabine derivatives.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000494:pharmacology*; D006224:Cricetinae; D003561:Cytarabine / Q000494:pharmacology* / Q000627:therapeutic use; D004247:DNA / Q000096:biosynthesis; D004952:Esters / Q000494:pharmacology; D006084:Graft Rejection / Q000187:drug effects; D006384:Hemagglutination / Q000187:drug effects; D006561:Herpes Simplex / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D037102:Lectins / Q000494:pharmacology; D007939:Leukemia L1210 / Q000188:drug therapy; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D012995:Solubility; D013329:Structure-Activity Relationship; D013936:Thymidine / Q000378:metabolism; D014316:Tritium
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D004952:Esters; D007166:Immunosuppressive Agents; D037102:Lectins; D003561:Cytarabine; D014316:Tritium; D004247:DNA; D013936:Thymidine